Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190992 | 0.98 | TDP1 (0.43) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| Quinoxaline SCHEMBL10762474 | 0.85 | CA1 (0.39) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL10612152 | 0.85 | ALDH1A1 (0.46) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL11761732 | 0.84 | ALDH1A1 (0.45) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL27484633 | 0.84 | ALDH1A1 (0.45) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| Lithium SCHEMBL29868510 | 0.84 | ALDH1A1 (0.45) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL4349616 | 0.84 | L3MBTL1 (0.42) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL28603286 | 0.84 | ALDH1A1 (0.45) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL1744678 | 0.83 | CA2 (0.49) | ALDH1A1KDM4ETDP1MEN1CYP3A4 | |
| SCHEMBL31489432 | 0.83 | L3MBTL1 (0.42) | ALDH1A1KDM4ETDP1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4559520-A1 | NOVEL AQP4 INHIBITORS | Origenis GmbH (DE) | 2025-05-28 | — | — | EP | disclosed |
| US-12213987-B2 | Prodrug salts | AEROMICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240299425-A1 | FORMULATIONS | AEROMICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117222416-A | Clay composition and method for improving animal performance | 礼蓝美国公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-0797635-B1 | NON-AQUEOUS INKS AND COATINGS CONTAINING CARBON PRODUCTS | CABOT CORP (US) | 2000-02-16 | — | — | EP | disclosed |
| CN-1219872-A | Compositions and methods for treating or preventing body passageway disorders | ANGIOTECH PHARM INC (CA) | 1999-06-16 | — | — | CN | disclosed |
| US-5713988-A | LABELS FOR CARDBOARD BOXES, METAL OR PLASTIC CONTAINERS | CABOT CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0797635-A2 | NON-AQUEOUS INKS AND COATINGS CONTAINING CARBON PRODUCTS | CABOT CORPORATION (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018694-A2 | NON-AQUEOUS INKS AND COATINGS CONTAINING CARBON PRODUCTS | CABOT CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0260901-A1 | Benzenesulphonamides useful as anti-arrythmic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0053890-B1 | PRODUCTION OF ARYL ACYLAMIDASES | The Public Health Laboratory Service Board (GB) | 1985-02-13 | — | — | EP | disclosed |
| US-4430433-A | CULTURES, PSEUDOMONAS, HYDROLYSIS OF N-ACETYL-4-HYDROXYANILINE TO 4-HYDROXYANILINE | PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) | 1984-02-07 | — | — | US | disclosed |
| EP-0060680-A1 | Process for formulating a medicated animal feed premix | ELI LILLY AND COMPANY (US) | 1982-09-22 | — | — | EP | disclosed |
| EP-0053890-A1 | Production of aryl acylamidases | The Public Health Laboratory Service Board (GB) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | PLCG2, DCTPP1, PLCG1 | ALDH1A1 2814/4885KDM4E 800/4885TDP1 1488/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | ALDH1A1 4070/4885KDM4E 1649/4885TDP1 2406/4885 |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | SLC34A2, SLC20A2, SLC34A3 | ALDH1A1 2093/4885KDM4E 1873/4885TDP1 2063/4885 |
| US-20240299425-A1 | FORMULATIONS | DCPS, PPIP5K2, PRCP | ALDH1A1 3336/4885KDM4E 2315/4885TDP1 3176/4885 |
| US-12213987-B2 | Prodrug salts | AQP4, AQP1, AQP3 | ALDH1A1 2612/4885KDM4E 3257/4885TDP1 2920/4885 |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | ALDH1A1 2408/4885KDM4E 3301/4885TDP1 3329/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | ALDH1A1 4133/4885KDM4E 2233/4885TDP1 2263/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | ALDH1A1 4069/4885KDM4E 1787/4885TDP1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.